MedTrace Logo

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

NCT06046248 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-04-20

No results posted yet for this study

Summary

This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.

Conditions

Interventions

DRUG

Belumosudil

200mg PO QD x 24 cycles (28-day cycle)

DRUG

Rituximab

375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Northside Hospital, Inc.

    lead OTHER

Principal Investigators

  • Scott Solomon, MD · BMTGA/Northside Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-29
Primary Completion
2026-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06046248 on ClinicalTrials.gov